Menu
| Date | Time | Session |
|---|---|---|
| 12 May | 18:30 | Guest arrivals and networking dinner |
| 13 May | 08:45 – 09:00 | Registrations |
| 13 May | 09:00 – 09:20 | Opening Keynote “Promises and Challenges of Big Data Analytics in Healthcare” Marc Ladanyi, MD – Memorial Sloan Kettering Cancer Center |
| 13 May | 09:20 – 09:40 | Keynote “Unlocking the Power of Data: AI-Driven Insights for Precision Medicine” Jurgi Camblong, Ph.D, MBA – SOPHiA GENETICS |
| 13 May | 09:40 – 09:50 | Spotlight “SOPHiA GENETICS Innovation Roadmap: What’s Next?” Philippe Menu, Ph.D, MBA – SOPHiA GENETICS |
| 13 May | 09:50 – 10:20 | Track “Pushing the Boundaries of Germline Analysis” Tamara Maas, Ph.D & Javier Botet – SOPHiA GENETICS |
| 13 May | 10:20 – 10:50 | Coffee Break & Networking |
| 13 May | 10:50 – 12:00 | Track “Overcoming Cancer Complexity: Real-World Impact of Genomic Innovations” • Elena Guerini Rocco, MD – European Institute of Oncology (IEO) • Geert Martens, MD, Ph.D – AZ Delta • Anne L’Hernault, Ph.D – AstraZeneca |
| 13 May | 12:00 – 13:00 | Lunch & Networking |
| 13 May | 13:00 – 13:45 | Track • Zhenyu Xu, Ph.D – SOPHiA GENETICS • Brigitte Maes, MD, Ph.D – Jessa Ziekenhuis |
| 13 May | 13:45 – 15:00 | Track • Thierry Colin, Ph.D – SOPHiA GENETICS • Sergio Marchini, Ph.D – IRCCS Humanitas Research Hospital • Olivier Michielin, MD, Ph.D – HUG • Thomas Di Maio – AstraZeneca |
| 13 May | 15:00 – 15:30 | Coffee Break & Networking |
| 13 May | 15:30 – 16:15 | Panel Discussion “AI and the Next Era of Precision Medicine” • John Philip – MSKCC • Prof. Léa Payen-Gay – Claude Bernard Lyon I • Antonio Gatti – Microsoft • Leonie DeVisser – Johnson & Johnson Moderator: Philippe Menu, Ph.D, MBA |
| 13 May | 16:15 – 16:30 | Closing Remarks – Ross Muken – SOPHiA GENETICS |
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
